Inovio Pharmaceuticals (INO) AI Stock Analysis

• Market Cap: $74.82M
• Dividend Yield: N/A
• Average Volume (3M): 803.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.80
• Revenue Growth: -60.52%
• EPS Growth: 42.41%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.51
• Shares Outstanding: 36,674,435
• 10 Day Avg. Volume: 1,104,416
• 30 Day Avg. Volume: 803,728
• PEG Ratio: -0.02
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -381.91
• Enterprise Value/Revenue: -23.21K
• Enterprise Value/Gross Profit: 20.60K
• Enterprise Value/Ebitda: 1.12
• 1Y Price Target: $8.25
• Price Target Upside: 285.51% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 51 Neutral
• Price Target: $2.00 ▼(-6.54%Downside)

Inovio Pharmaceuticals' overall stock score reflects significant financial challenges, despite some positive developments in their product pipeline and cost management. The technical analysis shows moderate strength, but valuation concerns persist due to ongoing losses.

Positive Factors

Clinical Efficacy

One-half of RRP patients treated with INO-3107 achieved a complete response and required no surgery in the second 12-month period when evaluated at the end of year two.

Regulatory Milestones

INO-3107 has been granted Breakthrough Therapy designation for the treatment of recurrent respiratory papillomatosis (RRP) by the FDA.

Safety Profile

No treatment-emergent serious adverse events were identified in RRP-002, indicating a favorable safety profile for INO-3107.

Negative Factors

Manufacturing Issues

Inovio Pharmaceuticals believes the device manufacturing issues for DNA immunotherapy INO-3107 have been resolved, supporting a BLA acceptance by YE25.

Regulatory Requirements

The company also needs to update IND and initiate a confirmatory trial before the BLA submission.

Trial Confirmation

The results increase confidence in a positive outcome from the planned placebo-controlled confirmatory trial of INO-3107.

Inovio Pharmaceuticals Business Overview & Revenue Model

Company Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

How the Company Makes Money

Inovio Pharmaceuticals makes money primarily through the development and commercialization of its DNA-based immunotherapy products. The company generates revenue through licensing agreements, collaborations, and research grants with larger pharmaceutical and biotechnology companies, as well as government and non-governmental organizations. Inovio's partnerships often involve upfront payments, milestone payments, and potential royalties on sales of products developed using its technology. Additionally, the company may receive funding from grants and contracts for specific research and development projects. As Inovio advances its product candidates through clinical trials, successful commercialization of these therapies could lead to significant revenue generation through direct sales or additional partnerships.

Inovio Pharmaceuticals Financial Statement Overview

Summary

Inovio Pharmaceuticals faces significant financial challenges, with persistent losses, negative cash flows, and lack of revenue growth. Despite a strong equity position, profitability concerns and reliance on financing are major issues.

Income Statement

Inovio Pharmaceuticals exhibits a challenging financial position with consistent negative net income and EBIT over the years. The company shows no revenue growth and gross profit margins are negative, indicating cost management issues or insufficient revenue to cover costs. The absence of gross profit and negative EBIT margins reflect the company's ongoing struggle with profitability.

Balance Sheet

The balance sheet reveals a relatively stable equity position with stockholders' equity being significantly higher than total debt, resulting in a low debt-to-equity ratio. However, the company has been heavily reliant on equity financing, as indicated by the substantial stockholders' equity compared to total assets. Despite the strong equity base, the company has not converted this into profitability or growth.

Cash Flow

Cash flow analysis indicates a negative operating and free cash flow, showing difficulties in generating cash from operations. The company has relied on financing activities to sustain operations, which may not be sustainable long-term. The absence of positive free cash flow growth further highlights challenges in cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	217.76K	217.76K	832.01K	10.26M	1.77M	7.41M
Gross Profit	-1.39M	-2.91M	-2.67M	4.77M	-2.96M	-86.83M
EBITDA	-25.12B	-103.95M	-130.39M	-270.90M	-296.56M	-149.56M
Net Income	-44.91B	-107.25M	-135.12M	-287.66M	-305.38M	-215.09M
Balance Sheet
Total Assets	87.27B	113.20M	170.95M	348.53M	495.94M	539.77M
Cash, Cash Equivalents and Short-Term Investments	68.36B	94.11M	145.29M	253.00M	401.31M	411.64M
Total Debt	11.27B	11.87B	30.21M	32.07M	33.02M	39.05M
Total Liabilities	36.02B	44.69M	53.60M	126.17M	96.27M	78.63M
Stockholders Equity	51.25B	68.50B	117.35M	222.36M	399.67M	461.14M
Cash Flow
Free Cash Flow	-111.28B	-104.56M	-124.69M	-217.18M	-216.94M	-179.50M
Operating Cash Flow	-111.28B	-104.08M	-124.37M	-216.22M	-215.71M	-177.98M
Investing Cash Flow	69.36B	104.07M	87.36M	109.59M	-175.34M	-58.80M
Financing Cash Flow	1.09B	51.48M	5.00M	81.84M	211.50M	465.28M

Inovio Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INO, the sentiment is Positive. The current price of 2.14 is above the 20-day moving average (MA) of 2.09, above the 50-day MA of 2.00, and below the 200-day MA of 3.01, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 54.59 is Neutral, neither overbought nor oversold. The STOCH value of 48.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INO.

Inovio Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
INO	51 Neutral	$74.82M	―	-132.44%	―	-60.52%	42.41%
VTGN	48 Neutral	$58.61M	―	-46.28%	―	-33.00%	54.91%
SAVA	43 Neutral	$89.37M	―	-70.59%	―	―	81.00%
IFRX	39 Underperform	$53.71M	―	-62.38%	―	178.84%	-40.60%
ABOS	36 Underperform	$67.24M	―	-55.68%	―	―	-57.45%
JSPR	35 Underperform	$86.23M	―	-101.34%	―	―	21.40%

Inovio Pharmaceuticals Corporate Events

Inovio Pharmaceuticals Holds Annual Stockholders Meeting

On May 20, 2025, Inovio Pharmaceuticals held its Annual Meeting of Stockholders where four proposals were considered. The proposals included the election of eight directors, the ratification of Ernst & Young LLP as the independent auditor, approval of executive compensation, and amendment of the 2023 Omnibus Incentive Plan. Each proposal received varying levels of support from the stockholders, reflecting the company’s ongoing governance and strategic planning efforts.

The most recent analyst rating on (INO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Inovio Pharmaceuticals stock, see the INO Stock Forecast page.